Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 12,400
-120 (-0.96%)
At close: Oct 24, 2025
Prestige BioPharma Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2019 - 2020 |
| 14,326 | 689.08 | 161.84 | - | - | Upgrade | |
Revenue Growth (YoY) | 1978.97% | 325.77% | - | - | - | Upgrade |
Cost of Revenue | 26,563 | 11,291 | 33.94 | 228.95 | 284.85 | Upgrade |
Gross Profit | -12,237 | -10,602 | 127.9 | -228.95 | -284.85 | Upgrade |
Selling, General & Admin | 23,307 | 19,108 | 58,231 | 54,422 | 16,432 | Upgrade |
Research & Development | 19,123 | 23,414 | - | - | - | Upgrade |
Amortization of Goodwill & Intangibles | 2,782 | 178.99 | - | - | - | Upgrade |
Other Operating Expenses | 520.59 | 1,326 | - | - | - | Upgrade |
Operating Expenses | 54,348 | 51,636 | -906.28 | 122,460 | 18,099 | Upgrade |
Operating Income | -66,585 | -62,238 | 1,034 | -122,689 | -18,384 | Upgrade |
Interest Expense | -7,626 | -7,404 | -950.8 | -18.85 | -6.2 | Upgrade |
Interest & Investment Income | 9,137 | 12,402 | 10,464 | 2,729 | 158.22 | Upgrade |
Earnings From Equity Investments | - | - | -16.96 | - | - | Upgrade |
Currency Exchange Gain (Loss) | 2,145 | -4,232 | -924.24 | -1,592 | -4,620 | Upgrade |
Other Non Operating Income (Expenses) | 7,397 | 6,693 | 4,034 | 2,282 | 414.8 | Upgrade |
EBT Excluding Unusual Items | -55,533 | -54,779 | 13,639 | -119,288 | -22,437 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 15,081 | Upgrade |
Gain (Loss) on Sale of Assets | -6.7 | 89.4 | 72.12 | 211.59 | -0.36 | Upgrade |
Asset Writedown | 59,462 | - | -15,807 | -91,573 | - | Upgrade |
Pretax Income | 3,923 | -54,689 | -2,095 | -210,649 | -7,357 | Upgrade |
Income Tax Expense | -248.48 | 408.68 | 763.28 | 800.66 | 34.08 | Upgrade |
Earnings From Continuing Operations | 4,171 | -55,098 | -2,859 | -211,450 | -7,391 | Upgrade |
Minority Interest in Earnings | 18,126 | 22,177 | 20,428 | - | - | Upgrade |
Net Income | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 | Upgrade |
Net Income to Common | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 | Upgrade |
Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 52 | Upgrade |
Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 52 | Upgrade |
Shares Change (YoY) | 0.44% | -0.22% | - | 16.46% | 20.98% | Upgrade |
EPS (Basic) | 370.20 | -549.00 | 292.35 | -3518.53 | -143.23 | Upgrade |
EPS (Diluted) | 370.20 | -549.00 | 292.35 | -3796.17 | -143.23 | Upgrade |
Free Cash Flow | -92,877 | -68,091 | -108,636 | -102,336 | -16,396 | Upgrade |
Free Cash Flow Per Share | -1542.04 | -1135.49 | -1807.71 | -1702.88 | -317.73 | Upgrade |
Gross Margin | -85.42% | - | 79.03% | - | - | Upgrade |
Operating Margin | -464.80% | -9032.13% | 639.01% | - | - | Upgrade |
Profit Margin | 155.64% | -4777.60% | 10855.90% | - | - | Upgrade |
Free Cash Flow Margin | -648.33% | -9881.47% | -67125.45% | - | - | Upgrade |
EBITDA | -44,785 | -45,971 | 12,684 | -118,822 | -16,717 | Upgrade |
EBITDA Margin | - | - | 7837.31% | - | - | Upgrade |
D&A For EBITDA | 21,801 | 16,267 | 11,650 | 3,867 | 1,667 | Upgrade |
EBIT | -66,585 | -62,238 | 1,034 | -122,689 | -18,384 | Upgrade |
EBIT Margin | - | - | 639.01% | - | - | Upgrade |
Advertising Expenses | 869.23 | 970.57 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.